Go Unlimited with Magzter GOLD

Go Unlimited with Magzter GOLD

Get unlimited access to 10,000+ magazines, newspapers and Premium stories for just

$149.99
 
$74.99/Year
The Perfect Holiday Gift Gift Now

Metal detector, cornerstone in quality management

Chronicle Pharmabiz

|

September 18, 2025

IDENTIFYING the source of contamination and maintaining quality norms and standards of hygiene can help manufacture safe and quality products stipulated to government norms.

- Dr D Mandal

Metal detector is a key cornerstone in quality control (QC) management for pharmaceutical processing sector. Metal detection forms a key part of product quality assurance (QA) in pharmaceuticals and helping to prove the quality of manufacturing process and compliance with regulations.

Currently available metal detectors utilize latest digital signal processing technology to detect and reject ferrous and nonferrous metals. Latest pharmaceutical detectors have advantages such as highest processing power, superior speed, accuracy with additional features like current good manufacturing practices, design and construction suited for the US health regulatory compliance and meet the demanding quality standards required by the industry.

Advancing quality inspection system

Pharmaceutical products safety norms and legislation continue to come under highly increasing scrutiny. Thorough risk assessments are enabled by the separation and speciation of elements in a drug product, allowing for more detailed evaluations of both the benefits and risks presented by elements within a particular sample.

More and more studies demonstrate that free elements and various bound states differ greatly in toxicity, the speciation of elements will become even more critical almost any stage of drug development and manufacturing, impurities, contaminants, and residuals can be introduced into pharmaceuticals and biopharmaceuticals.

The presence of elemental impurities in raw materials, APIs, drug product, and packaging materials can cause significant disruption to even the most robust path-to-market, as drug products will not comply with necessary regulations to ensuring product safety and efficacy.

MORE STORIES FROM Chronicle Pharmabiz

Chronicle Pharmabiz

US FDA fortifies alliance with Telangana DCA

A high-level delegation from the US FDA concluded a significant meeting with the DCA in Telangana, two days ago, at the DCA office in Hyderabad.

time to read

2 mins

December 11, 2025

Chronicle Pharmabiz

India exploring possibilities to expand WHO standards for Indian medicines

INDIA is looking at possibilities to expand the World Health Organisation (WHO) global benchmarking standards for medicines, in order to unify and strengthen the drug regulatory mechanism for safety, quality and efficacy of medicines sold in the country.

time to read

1 min

December 11, 2025

Chronicle Pharmabiz

Eli Lilly gets US FDA approval for Jaypirca

Eli Lilly and Company announced that the US Food and Drug Administration (FDA) has granted approval to Jaypirca (pirtobrutinib, 100 mg & 50 mg tablets) for the treatment of adults with relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent Bruton tyrosine kinase (BTK) inhibitor.

time to read

1 mins

December 11, 2025

Chronicle Pharmabiz

Haryana DCA focuses on quality overhaul

THE Haryana drug control administration (DCA) is undertaking a major organizational overhaul focused on quality system upgrades and regulatory capacity building, particularly in response to the revised Schedule M norms.

time to read

2 mins

December 11, 2025

Chronicle Pharmabiz

DoC seeks inputs on trade issues faced with Japan

THE Department of Commerce (DoC), under the Union Commerce Ministry, has sought inputs from the industry on specific issues being faced in pharma trade with Japan.

time to read

1 min

December 11, 2025

Chronicle Pharmabiz

AIOCD asks traders to strictly comply with ban on 35 FDCs

THE All India Organisation of Chemists and Druggists (AIOCD) has issued an urgent internal circular to all its state and Union territory trade bodies, demanding immediate and strict compliance with the ban on 35 fixed dose combinations (FDCs).

time to read

3 mins

December 11, 2025

Chronicle Pharmabiz

US FDA approves Bristol Myers Squibb's Breyanzi

Bristol Myers Squibb announced that the US Food and Drug Administration (FDA) has granted approval of Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment of adult patients with relapsed or refractory (R/R) marginal zone lymphoma (MZL) who have received at least two prior lines of systemic therapy.

time to read

2 mins

December 11, 2025

Chronicle Pharmabiz

CN Water presents AQU@Sense MB

CN Water is now combining core water-system expertise with digital assurance has launched AQU@Sense which delivers microbial test results in under 30 minutes, replacing traditional 5 to 7 days culture based methods.

time to read

1 min

December 11, 2025

Chronicle Pharmabiz

Pharma logistics sees policy push as key catalyst for growth

INDIAN pharma's logistics sector is getting major boost from emerging policy support.

time to read

2 mins

December 11, 2025

Chronicle Pharmabiz

Lack of financial aid, expertise mar MSME prospects to meet revised Sch M deadline

INDUSTRY experts have raised alarm that lack of financial assistance and guidance on technical expertise have marred pharma MSMEs’ prospects to comply with revised Schedule M guidelines of December 31, 2025.

time to read

2 mins

December 11, 2025

Listen

Translate

Share

-
+

Change font size

Holiday offer front
Holiday offer back